Northern Trust
NVLN

Northern Trust’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Northern Trust’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-133,018
Closed -$465K – 4348
2018
Q1 		$465K Sell
133,018
-130
-0.1% -$551 ﹤0.01% 3593
2017
Q4 		$415K Sell
133,148
-2,717
-2% -$13.1K ﹤0.01% 3599
2017
Q3 		$955K Buy
135,865
+306
+0.2% +$2.45K ﹤0.01% 3448
2017
Q2 		$1.25M Buy
+135,559
New +$1.31M ﹤0.01% 3382

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Northern Trust's NVLN Position: Q2 2018 in Review

Northern Trust sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2018, closing a stake of 133,018 shares — an estimated $465K sold.

Northern Trust first reported a position in NVLN in Q2 2017 and held it in 4 quarters. The position peaked at $1.25M in Q2 2017. 53 funds tracked by Wall St. Rank hold NVLN as of Q2 2018.

  • Northern Trust reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2018 after selling out during the quarter.
  • Northern Trust sold 133,018 Novelion Therapeutics Inc. Common Shares shares in Q2 2018, an estimated $465K.
  • Northern Trust first reported a position in Novelion Therapeutics Inc. Common Shares in Q2 2017 and held it in 4 quarters.
  • Northern Trust's Novelion Therapeutics Inc. Common Shares position peaked at $1.25M in Q2 2017.
  • 53 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2018.

Based on Northern Trust's 13F filing for Q2 2018, filed 14 Aug 2018.